Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist

Journal of Immunotherapy

Volumn 27, Issue 6, 2004, Pages 460-471

  Krieg, Arthur M ^a   Efler, Susan M ^b   Wittpoth, Michael ^a   Al Adhami, Mohammed J ^a   Davis, Heather L ^b  

^a PFIZER INC   (United States)

^b Coley Pharmaceutical Canada ^*  (Canada)

Author keywords

B cell; CpG; Dendritic cell; Immune activation; IP 10; Lymphocyte activation; Toll like receptor

Indexed keywords

ALPHA INTERFERON; C REACTIVE PROTEIN; CHEMOKINE; CPG 7909; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOLOGIC AGENT; INTERLEUKIN 12; INTERLEUKIN 6; OLIGODEOXYNUCLEOTIDE DERIVATIVE; PROTEIN P40; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 AGONIST; UNCLASSIFIED DRUG; ALPHA CHEMOKINE; CELL SURFACE RECEPTOR; CXC CHEMOKINE IP 10; CXC CHEMOKINE IP-10; MEMBRANE PROTEIN; OLIGODEOXYRIBONUCLEOTIDE; TLR9 PROTEIN, HUMAN; TOLL LIKE RECEPTOR;

ADULT; ARTHRALGIA; ARTICLE; AUTOIMMUNITY; CELL TYPE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CPG ISLAND; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DETERMINATION; DRUG TOLERABILITY; EDEMA; ERYTHEMA; EXTRAVASATION; FATIGUE; FEVER; FLU LIKE SYNDROME; GENE EXPRESSION; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNITY; IMMUNOSTIMULATION; IMMUNOTHERAPY; INFLAMMATION; INJECTION SITE; LYMPHADENOPATHY; LYMPHOCYTE; MONOCYTE; MYALGIA; NEUTROPHIL; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECEPTOR UPREGULATION; RHINOPHARYNGITIS; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SPECIES DIFFERENCE; SYMPTOMATOLOGY; TH1 CELL; BLOOD; DRUG EFFECT; DRUG POTENTIATION; IMMUNOLOGY; INNATE IMMUNITY; INTRAVENOUS DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION;

AUTOIMMUNITY; C-REACTIVE PROTEIN; CHEMOKINES; CHEMOKINES, CXC; CYTOKINES; HUMANS; IMMUNITY, NATURAL; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MEMBRANE GLYCOPROTEINS; OLIGODEOXYRIBONUCLEOTIDES; RECEPTORS, CELL SURFACE; TH1 CELLS; TOLL-LIKE RECEPTOR 9; TOLL-LIKE RECEPTORS;

EID: 7444242674     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200411000-00006     Document Type: Article

References (76)

1. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197-216.
2. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376.
3. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374:546-549.
4. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709-760.
5. Uhlmann E, Vollmer J. Recent advances in the development of immunostimulatory oligonucleotides. Curr Opin Drug Discov Dev. 2003;6:204-217.
6. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740-745.
7. Bauer S, Kirschning CJ, Hacker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA. 2001;98:9237-9242.
8. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001;194:863-870.
9. Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol. 2002;168:4531-4537.
10. Dalpke AH, Schafer MK, Frey M, et al. Immunostimulatory CpG-DNA activates murine microglia. J Immunol. 2002;168:4854-4863.
11. Pillarisetty VG, Shah AB, Miller G, et al. Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition. J Immunol. 2004;172:1009-1017.
12. Rankin R, Pontarollo R, Ioannou X, et al. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 2001;11:333-340.
13. Yi AK, Chang M, Peckham DW, et al. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. [published erratum appears in J Immunol 1999 Jul 15;163(2):1093] J Immunol 1998;160:5898-5906.
14. Yi AK, Chang M, Peckham DW, et al. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. [published erratum appears in J Immunol 1999 Jul 15;163(2):1093] J Immunol 1998;160:5898-5906.
15. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol. 2000;164:944-953.
16. Hartmann G, Weeratna RD, Ballas ZK, et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol. 2000;164:1617-1624.
17. Latz E, Schoenemeyer A, Visintin A, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol. 2004;5:190-198.
18. Ahmad-Nejad P, Hacker H, Rutz M, et al. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol. 2002;32:1958-1968.
19. Blackwell SE, Krieg AM. CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha. J Immunol. 2003;170:4061-4068.
20. Klinman DM, Yi AK, Beaucage SL, et al. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ. Proc Natl Acad Sci USA. 1996;93:2879-2883.
21. Yi AK, Klinman DM, Martin TL, et al. Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. J Immunol. 1996;157:5394-5402.
22. Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol. 1996;157:1840-1845.
23. Krug A, Rothenfusser S, Hornung V, et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol. 2001;31:2154-2163.
24. Yousefi S, Cooper PR, Potter SL, et al. Cloning and expression analysis of a novel G-protein-coupled receptor selectively expressed on granulocytes. J Leukoc Biol. 2001;69:1045-1052.
25. Kadowaki N, Antonenko S, Liu YJ. Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c(-) type 2 dendritic cell precursors and CD11c(+) dendritic cells to produce type I IFN. J Immunol. 2001;166:2291-2295.
26. Zhao Q, Temsamani J, Zhou RZ, et al. Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 1997;7:495-502.
27. Krug A, Towarowski A, Britsch S, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 2001;31:3026-3037.
28. Heikenwalder M, Polymenidou M, Junt T, et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med. 2004;10:187-192.
29. Cowdery JS, Chace JH, Yi AK, et al. Bacterial DNA induces NK cells to produce IFN-γ in vivo and increases the toxicity of lipopolysaccharides. J Immunol 1996;156:4570-4575.
30. Sparwasser T, Miethke T, Lipford G, et al. Bacterial DNA causes septic shock. Nature. 1997;386:336-337.
31. Sparwasser T, Hultner L, Koch ES, et al. Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J Immunol. 1999;162:2368-2374.
32. Krieg AM. CpG DNA: trigger of sepsis, mediator of protection, or both? Scand J Infect Dis. 2003;35:653-659.
33. Yeo SJ, Yoon JG, Hong SC, et al. CpG DNA induces self and cross-hyporesponsiveness of RAW264.7 cells in response to CpG DNA and lipopolysaccharide: alterations in IL-1 receptor-associated kinase expression. J Immunol 2003;170:1052-1061.
34. Klinman DM, Conover J, Coban C. Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect Immun. 1999;67:5658-5663.
35. Lazarus R, Klimecki WT, Raby BA, et al. Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage disequilibrium, and haplotypes in three U.S. ethnic groups and exploratory case-control disease association studies. Genomics. 2003;81:85-91.
36. Biron CA, Nguyen KB, Pien GC. Innate immune responses to LCMV infections: natural killer cells and cytokines. Curr Top Microbiol Immunol. 2002;263:7-27.
37. Astsaturov I, Petrella T, Bagriacik EU, et al. Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines. Clin Cancer Res. 2003;9:4347-4355.
38. Akbar AN, Lord JM, Salmon M. IFN-alpha and IFN-beta: a link between immune memory and chronic inflammation. Immunol Today. 2000;21:337-342.
39. Le Bon A, Etchart N, Rossmann C, et al. Cross-priming of CD8+ T cells stimulated by virus-induced type 1 interferon. Nat Immunol 2003;4:1009-1015.
40. Sprent J, Surh CD. T cell memory. Annu Rev Immunol. 2002;20:551-579.
41. Hilkens CM, Schlaak JF, Kerr IM. Differential responses to IFN-alpha subtypes in human T cells and dendritic cells. J Immunol. 2003;171:5255-5263.
42. Pertl U, Luster AD, Varki NM, et al. IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J Immunol. 2001;166:6944-6951.
43. Tannenbaum CS, Tubbs R, Armstrong D, et al. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol. 1998;161:927-932.
44. Narvaiza I, Mazzolini G, Barajas M, et al. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol. 2000;164:3112-3122.
45. Duramad O, Fearon KL, Chan JH, et al. IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences. Blood. 2003;102:4487-4492.
46. Rothenfusser S, Hornung V, Ayyoub M, et al. CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood. 2004;103:2162-2169.
47. Lore K, Betts MR, Brenchley JM, et al. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J Immunol 2003;171:4320-4328.
48. Serra P, Amrani A, Yamanouchi J, et al. CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. Immunity. 2003;19:877-889.
49. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science. 2003;299:1033-1036.
50. Conant SB, Swanborg RH. Autoreactive T cells persist in rats protected against experimental autoimmune encephalomyelitis and can be activated through stimulation of innate immunity. J Immunol. 2004;172:5322-5328.
51. Yang Y, Huang CT, Huang X, et al. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol. 2004;5:508-515.
52. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43:1431-1442.
53. Blanco P, Palucka AK, Gill M, et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001;294:1540-1543.
54. Ronnblom L, Alm GV. A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med. 2001;194:F59-F63.
55. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA. 2003;100:2610-2615.
56. Crow MK. Interferon-alpha: a new target for therapy in systemic lupus erythematosus? Arthritis Rheum. 2003;48:2396-2401.
57. Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 2002;416:603-607.
58. Viglianti GA, Lau CM, Hanley TM, et al. Activation of autoreactive B cells by CpG dsDNA. Immunity. 2003;19:837-847.
59. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004;4:249-259.
60. Geary R, Yu R, Leeds J, et al. Pharmacokinetic properties in animals. In: Crooke ST, ed. Antisense Drug Technology Principles, Strategies, and Applications. New York: Marcel Dekker, Inc, 2001:119-154.
61. Jung J, Yi AK, Zhang X, et al. Distinct response of human B cell subpopulations in recognition of an innate immune signal, CpG DNA. J Immunol. 2002;169:2368-2373.
62. Verthelyi D, Ishii KJ, Gursel M, et al. Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. J Immunol. 2001;166:2372-2377.
63. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science. 2002;298:2199-2202.
64. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood. 2003;101:4500-4504.
65. Vollmer J, Weeratna R, Fayette P, et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol. 2004;34:251-262.
66. Marshall JD, Fearon K, Abbate C, et al. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol. 2003;73:781-792.
67. Hartmann G, Battiany J, Poeck H, et al. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol 2003;33:1633-1641.
68. Weiner GJ, Liu HM, Wooldridge JE, et al. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA. 1997;94:10833-10837.
69. Lipford GB, Bauer M, Blank C, et al. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol. 1997;27:2340-2344.
70. Chu RS, Targoni OS, Krieg AM, et al. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med. 1997;186:1623-1631.
71. Davis HL, Weeratna R, Waldschmidt TJ, et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. [published erratum appears in J Immunol 1999 Mar 1;162(5):3103] J Immunol. 1998;160:870-876.
72. Davis HL, Weeratna R, Waldschmidt TJ, et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. [published erratum appears in J Immunol 1999 Mar 1;162(5):3103] J Immunol. 1998;160:870-876.
73. Roman M, Martin-Orozco E, Goodman JS, et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med. 1997;3:849-854.
74. Jones TR, Obaldia N III, Gramzinski RA, et al. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine. 1999;17:3065-3071.
75. Davis HL, Suparto II, Weeratna RR, et al. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine. 2000;18:1920-1924.
76. Halperin SA, Van Nest G, Smith B, et al. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine. 2003;21:2461-2467.